News: BDA BOD Australia Says Executed Letter Of Intent With Tilman SA, page-20

https://smallcaps.com.au/cannabis-stocks-asx-ultimate-guide/

Bod Australia (ASX: BDA)

Skincare and natural medicines developer Bod Australia’s medicinal cannabis oil called Medicabilis is currently being prescribed to patients through Australia’s SAS B scheme.

The company has also developed a cannabis-based sub-lingual (dissolved under the tongue) wafer product, which it evaluated in a “world-first” blind clinical trial last July. Blinded conditions refer to both the patient and clinician not knowing if they are using an active drug or placebo.

Bod claims its wafer system is an easily administered, pharmaceutical-grade product with higher absorption than many existing products.

The next phase of the clinical trial will test the absorption rate of the wafer compared to Bod’s Medicabilis oil.

In November 2018, the company obtained an export licence allowing it to export Australian-made cannabis products to international markets including Belgium, Switzerland and the UK.

Bod’s business is underpinned by two exclusive global partnerships – a supply and collaboration agreement with Swiss Botanicals extracts manufacturer Linnea SA and a licensing deal with Singapore-listed iX Biopharma (SGC: 42C) to use its wafer technology.

At the start of March, Bod announced it will begin supplying a pharmaceutical-grade cannabis extract to Australian medicinal cannabis research group Lambert Initiative for use in a clinical trial for Tourette’s Syndrome.

It also has a commercial relationship with the Australia’s largest pharmacy retailer, Chemist Warehouse Group, to dispense its Medicabilis oil.

Bod’s other products include herbal and pregnancy supplements and the True Earth skincare range, made using hemp seed oil.

Formulations for a nutraceutical range using CBD extract is also currently being developed for Europe and the UK.